|RMD -- USA Stock|| |
USD 109.49 0.48 0.44%
Non-Executive Chairman of the Board
Dr. Peter Farrell, Ph.D. is NonExecutive Chairman of the Board, Founder of the Company. Dr. Farrell also served as chief executive officer from July 1990 until December 2007, and from February 2011 until March 2013. Dr. Farrell served as executive chairman of the board from December 2007 until February 2011, and from March 2013 through December 2013. Since January 1, 2014, he was a nonofficer employee of ResMed. From July 1984 to June 1989, Dr. Farrell served as vice president, research and development at various subsidiaries of Baxter International, Inc., and from August 1985 to June 1989, he also served as managing director of the Baxter Center for Medical Research Pty Ltd., a Baxter subsidiary. From January 1978 to December 1989, he was foundation director of the Graduate School for Biomedical Engineering at the University of New South Wales, where he currently serves as a visiting professor and as chairman of the UNSW Centre for Innovation and Entrepreneurship. He also serves on the Visiting Committee of the Health Sciences Technology Program at the Massachusetts Institute of Technology and on the MIT Dean of Engineerings Advisory Council
Age: 74 Chairman Since 2014 Ph.D
Farrell serves on two faculty advisory boards at the University of California, San Diego: the Rady Business School and the Jacobs Engineering School. He holds a B.E. in chemical engineering with honors from the University of Sydney, an S.M. in chemical engineering from the Massachusetts Institute of Technology, a Ph.D. in chemical engineering and bioengineering from the University of Washington, Seattle and a D.Sc. from the University of New South Wales for research contributions in the field of treatment with the artificial kidney. Since 2005, Dr. Farrell was a director of NuVasive, Inc., a NASDAQlisted company which develops and markets products for the surgical treatment of spine disorders. From 2007 through 2014, he was the nonexecutive chairman of the board of QRx Pharma, an ASXlisted specialty pharmaceutical company.